#

+1 (917) 893 7512

  • #
  • #
  • #
#
Global Intravenous (IV) Iron Drugs Market Report: Size, Trends and Forecasts (2018-2022)

Global Intravenous (IV) Iron Drugs Market: Size, Trends and Forecasts (2018-2022)

Publish Date:Oct 2018
No. of Pages:102

Format : Adobe Reader (PDF) Instant delivery

US$ 1,600.00

Scope of the Report

The report titled “Global Intravenous (IV) Iron Drugs Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global intravenous (IV) iron drugs market by value, by product, by type, by region, etc. The report also provides a regional analysis of the intravenous (IV) iron drugs market, including the following regions: The US and Europe. The report also provides a detailed analysis of the US intravenous (IV) iron drugs market by value, by products and by indication.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global intravenous (IV) iron drugs market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global intravenous (IV) iron drugs market is highly fragmented with many intravenous (IV) iron drugs market players operating worldwide. Some intravenous (IV) iron drugs market players operating on a local level while other players operating on a regional and global level. The manufacturers of intravenous (IV) iron drugs market produce intravenous iron drugs for different indications, with different iron content and in different doses.

However, the competition in the global intravenous (IV) iron drugs market is dominated by few intravenous iron drugs manufacturers. Further, key players of the intravenous (IV) iron drugs market are Vifor Pharma AG, Sanofi, AMAG Pharmaceuticals, Inc. and Daiichi Sankyo Co., Ltd. are also profiled with their financial information and respective business strategies.

Country Coverage

The US
Europe

Company Coverage

Vifor Pharma AG
Sanofi
AMAG Pharmaceuticals, Inc.
Daiichi Sankyo Co., Ltd.

Executive Summary

Iron is one of the most essential mineral found in the human body. About 70% of the iron in the body is present in the red blood cells, called hemoglobin. Hemoglobin is required in the body to transport oxygen throughout the body via the blood. Deficiency of iron in the human body leads to severe health problems, which are associated with morbidity and mortality. To maintain the required level of iron in the body, iron supplements are given to the patients.

Iron supplements can be given in two forms: oral iron drugs and intravenous (IV) iron drugs. Oral iron drugs can be in the form of capsules, tablets or liquid drops. Intravenous iron drugs are given by injecting iron directly inside the body with a needle through a vein.

Intravenous iron drugs are favorably more preferred over oral iron drugs due to less side effects profile (oral iron drugs are not tolerable for many patients due to the poor gastrointestinal side effect); greater efficacy & better absorption (intravenous iron drugs are transported to the bone marrow through blood without need for absorption in the gut) and ensuring more efficient treatment (intravenous therapy allows larger dose of treatment over a short period of time).

Intravenous iron drugs have a long history with continuously evolving new generation intravenous iron drugs. The intravenous (IV) iron drugs market can be segmented on the basis of product, type and indication.

The global intravenous (IV) iron drugs market has increased at a significant CAGR during the years 2013-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The intravenous (IV) iron drugs market is expected to increase due to aging population, growing chronic diseases, escalating diabetic population, rising number of patients with chronic kidney disease, surge in the number of people with cancer, etc. Yet the market faces some challenges such as shift from Erythropoietin Stimulating Agents (ESAs) to HIF inhibitors, side effects associated with the use of intravenous iron drugs, etc.

1. Executive Summary

2. Introduction

2.1 Iron Supplements: An Analysis
2.1.1 Types of Iron Supplements

2.2 Intravenous Iron Drugs: An Analysis
2.2.1 Main Clinical Indications for Intravenous (IV) Iron Treatment
2.2.2 Reasons Favoring Intravenous Iron Use Over Oral Iron 
2.2.3 Side Effects and Complications 

2.3 Intravenous Iron Drugs Segmentation: An Overview
2.3.1 Intravenous Iron Drugs Segmentation by Product
2.3.2 Intravenous Iron Drugs Segmentation by Type
2.3.3 Intravenous Iron Drugs Segmentation by Indication

3. Global Market Analysis

3.1 Global Iron Drugs Market: An Analysis

3.1.1 Global Iron Drugs Market by Value
3.1.2 Global Iron Drugs Market by Segments (Oral Iron Drugs and Intravenous Iron Drugs)
3.1.3 Global Oral Iron Drugs Market by Value

3.2 Global Intravenous (IV) Iron Drugs Market: An Analysis

3.2.1 Global IV Iron Drugs Market by Value
3.2.2 Global IV Iron Drugs Market by Product (Injectafer/Ferinject, Venofer and Other Products)
3.2.3 Global IV Iron Drugs Market by Type (Ferric Carboxymaltose, Sucrose, Dextran and Others)
3.2.4 Global IV Iron Drugs Market by Region (The US, Europe and ROW)

3.3 Global Intravenous (IV) Iron Drugs Market: Product Analysis

3.3.1 Global Injectafer/Ferinject IV Iron Drugs Market by Value 
3.3.2 Global Venofer IV Iron Drugs Market by Value
3.3.3 Global Other IV Iron Drugs Market by Value

3.4 Global Intravenous (IV) Iron Drugs Market: Type Analysis

3.4.1 Global Ferric Carboxymaltose IV Iron Drugs Market by Value
3.4.2 Global Sucrose IV Iron Drugs Market by Value
3.4.3 Global Dextran IV Iron Drugs Market by Value

4. Regional Market Analysis

4.1 The US Intravenous (IV) Iron Drugs Market: An Analysis

4.1.1 The US IV Iron Drugs Market by Value 
4.1.2 The US IV Iron Drugs Market by Products (Venofer, Injectafer and Other Products)
4.1.3 The US IV Iron Drugs Market by Indication (Chronic Kidney Disease, Iron Deficiency Anemia, Inflammatory Bowel Disease, Oncology and Heart Failure)

4.2 The US Intravenous (IV) Iron Drugs Market: Product Analysis

4.2.1 The US Injectafer IV Iron Drugs Market by Value 
4.2.2 The US Injectafer IV Iron Drugs Market by Indication (Iron Deficiency Anemia, Inflammatory Bowel Disease, Oncology, Chronic Kidney Disease, Heart Failure and Other)
4.2.3 The US Iron Deficiency Anemia (IDA) Injectafer IV Iron Drugs Market by Value 
4.2.4 The US Inflammatory Bowel Disease (IBD) Injectafer IV Iron Drugs Market by Value 
4.2.5 The US Oncology Injectafer IV Iron Drugs Market by Value 
4.2.6 The US Chronic Kidney Disease (CKD) Injectafer IV Iron Drugs Market by Value 
4.2.7 The US Heart Failure Injectafer IV Iron Drugs Market by Value 
4.2.8 The US Other Injectafer IV Iron Drugs Market by Value 
4.2.9 The US Venofer IV Iron Drugs Market by Value 
4.2.10 The US Other IV Iron Drugs Market by Value 

4.3 The US Intravenous (IV) Iron Drugs Market: Indication Analysis

4.3.1 The US Iron Deficiency Anemia (IDA) IV Iron Drugs Market by Value 
4.3.2 The US Inflammatory Bowel Disease (IBD) IV Iron Drugs Market by Value 
4.3.3 The US Oncology IV Iron Drugs Market by Value 
4.3.4 The US Chronic Kidney Disease (CKD) IV Iron Drugs Market by Value 
4.3.5 The US Heart Failure IV Iron Drugs Market by Value 

4.4 Europe Intravenous (IV) Iron Drugs Market: An Analysis

4.4.1 Europe IV Iron Drugs Market by Value 

5. Market Dynamics

5.1 Growth Driver
5.1.1 Rising Disposable Income
5.1.2 Aging Population
5.1.3 Growing Chronic Diseases
5.1.4 Escalating Diabetic Population
5.1.5 Increasing Prevalence of Anemia among Pregnant Women
5.1.6 Soaring Number of Patients with Chronic Kidney Disease (CKD)
5.1.7 Increasing Number of Patients with End-Stage-Renal-Disease (ESRD)
5.1.8 Surge in the Number of People with Cancer

5.2 Challenges
5.2.1 Shift from Erythropoietin Stimulating Agents (ESAs) to HIF Inhibitors 
5.2.2 Side Effects Associated with the Use of Intravenous Iron Drugs

5.3 Market Trends
5.3.1 Increasing Healthcare Expenditure in Emerging Economies 
5.3.2 Increasing Use of Intravenous Iron Drugs over Oral Iron Drugs
5.3.3 Emerging Second and Third Generation Intravenous Iron Drugs
5.3.4 Evolution of Combination Products

6. Competitive Landscape

6.1 Global Intravenous (IV) Iron Drugs Market Players: A Financial Comparison
6.2 Global Intravenous (IV) Iron Drugs Market Players: Product Comparison
6.3 Global Intravenous (IV) Iron Drugs Market Players by FDA Drug Approval

7. Company Profiles

7.1 Vifor Pharma AG
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy

7.2 Sanofi 
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy

7.3 AMAG Pharmaceuticals, Inc.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy

7.4 Daiichi Sankyo Co., Ltd.
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
Figure 1: Types of Iron Supplements
Figure 2: Main Clinical Indications for Intravenous (IV) Iron Treatment
Figure 3: Reasons Favoring Intravenous Iron Use Over Oral Iron
Figure 4: Side Effects and Complications
Figure 5: Intravenous Iron Drugs Segmentation by Product
Figure 6: Intravenous Iron Drugs Segmentation by Type
Figure 7: Intravenous Iron Drugs Segmentation by Indication
Figure 8: Global Iron Drugs Market by Value; 2017 (US$ Billion)
Figure 9: Global Iron Drugs Market by Segments; 2017 (Percentage, %)
Figure 10: Global Oral Iron Drugs Market by Value; 2017-2022 (US$ Million)
Figure 11: Global IV Iron Drugs Market by Value; 2013-2017 (US$ Billion)
Figure 12: Global IV Iron Drugs Market by Value; 2018-2022 (US$ Billion)
Figure 13: Global IV Iron Drugs Market by Product; 2017 (Percentage, %)
Figure 14: Global IV Iron Drugs Market by Type; 2017 (Percentage, %)
Figure 15: Global IV Iron Drugs Market by Region; 2017 (Percentage, %)
Figure 16: Global Injectafer/Ferinject IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 17: Global Injectafer/Ferinject IV Iron Drugs Market by Value; 2018-2022 (US$ Billion)
Figure 18: Global Venofer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 19: Global Venofer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 20: Global Other IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 21: Global Other IV Iron Drugs Market by Value; 2018-2022 (US$ Billion)
Figure 22: Global Ferric Carboxymaltose IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 23: Global Ferric Carboxymaltose IV Iron Drugs Market by Value; 2018-2022 (US$ Billion)
Figure 24: Global Sucrose IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 25: Global Sucrose IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 26: Global Dextran IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 27: Global Dextran IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 28: The US IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 29: The US IV Iron Drugs Market by Value; 2018-2022 (US$ Billion)
Figure 30: The US IV Iron Drugs Market by Products; 2017 (Percentage, %)
Figure 31: The US IV Iron Drugs Market by Indication; 2017 (Percentage, %)
Figure 32: The US Injectafer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 33: The US Injectafer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 34: The US Injectafer IV Iron Drugs Market by Indication; 2017 (Percentage, %)
Figure 35: The US Iron Deficiency Anemia (IDA) Injectafer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 36: The US Iron Deficiency Anemia (IDA) Injectafer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 37: The US Inflammatory Bowel Disease (IBD) Injectafer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 38: The US Inflammatory Bowel Disease (IBD) Injectafer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 39: The US Oncology Injectafer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 40: The US Oncology Injectafer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 41: The US Chronic Kidney Disease (CKD) Injectafer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 42: The US Chronic Kidney Disease (CKD) Injectafer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 43: The US Heart Failure Injectafer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 44: The US Heart Failure Injectafer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 45: The US Other Injectafer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 46: The US Other Injectafer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 47: The US Venofer IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 48: The US Venofer IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 49: The US Other IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 50: The US Other IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 51: The US Iron Deficiency Anemia (IDA) IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 52: The US Iron Deficiency Anemia (IDA) IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 53: The US Inflammatory Bowel Disease (IBD) IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 54: The US Inflammatory Bowel Disease (IBD) IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 55: The US Oncology IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 56: The US Oncology IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 57: The US Chronic Kidney Disease (CKD) IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 58: The US Chronic Kidney Disease (CKD) IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 59: The US Heart Failure IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 60: The US Heart Failure IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 61: Europe IV Iron Drugs Market by Value; 2016-2017 (US$ Million)
Figure 62: Europe IV Iron Drugs Market by Value; 2018-2022 (US$ Million)
Figure 63: Global Disposable Income Growth rate; 2012-2016 (Percentage, %)
Figure 64: Global Aging Population by Gender; 2011-2017 (Trillion)
Figure 65: Global Chronic Diseases Growth Rate; 2016-2025 (Percentage, %)
Figure 66: Global Diabetic Population by Region; 2017 & 2045 (Million)
Figure 67: Global Prevalence of Anemia among Pregnant Women; 2011-2016 (Percentage, %)
Figure 68: The US and Europe Number of Patients with Chronic Kidney Disease (CKD); 2015-2022 (Million)
Figure 69: Global End-Stage-Renal-Disease (ESRD) Patients; 2015-2022 (Thousand)
Figure 70: Number of End-Stage-Renal-Disease Patients on Dialysis by Region; 2017-2022 (Thousand)
Figure 71: Global Number of People with Cancer by Age; 2011-2016 (Million)
Figure 72: Global Treatment Rate with ESAs in Non-Dialysis CKD; 2008-2016 (Percentage, %)
Figure 73: Emerging Economies Healthcare Expenditure; 1995-2022 (US$ Trillion)
Figure 74: Vifor Pharma AG Net Sales; 2013-2017 (US$ Million)
Figure 75: Vifor Pharma AG Net Sales by Region; 2017 (Percentage, %)
Figure 76: Evotech AG Revenues; 2013-2017 (US$ Million)
Figure 77: Sanofi Net Sales; 2013-2017 (US$ Billion)
Figure 78: Sanofi Net Sales by Segments; 2017 (Percentage, %)
Figure 79: Sanofi Net Sales by Region; 2017 (Percentage, %)
Figure 80: AMAG Pharmaceuticals, Inc. Total Revenue; 2013-2017 (US$ Million)
Figure 81: AMAG Pharmaceuticals, Inc. Total Revenue by Segments; 2017 (Percentage, %)
Figure 82: Daiichi Sankyo Co., Ltd. Revenue; 2014-2018 (US$ Billion)
Figure 83: Daiichi Sankyo Co., Ltd. Revenue by Products; 2018 (Percentage, %)
Figure 84: Daiichi Sankyo Co., Ltd. Revenue by Region; 2018 (Percentage, %)
Table 1: Global Intravenous (IV) Iron Drugs Market Players: A Financial Comparison; 2017/2018
Table 2: Global Intravenous (IV) Iron Drugs Market Players: Product Comparison
Table 3: Global Intravenous (IV) Iron Drugs Market Players by FDA Drug Approval